Merck Millipore celebrates 40 years of first class sterility testing solutions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Millipore celebrates 40 years of first class sterility testing solutions

In 1974, Merck Millipore was the first to market a closed filtration device: Steritest™. Since this time, through dedicated research & development, we have been instrumental in raising the industry's standards – reducing the risk of false positive and negative results, increasing reliability and improving workflow for microbiologists around the world.

We are a one-stop shop that offers an extensive portfolio of quality control products, as well as preventive maintenance, training, validation support and much more.
As we step into the future, Merck Millipore will continue providing reliable high quality products and comprehensive first-class services.

Our latest offer: a rapid sterility testing solution providing results within only 5 days.

40 years is just the beginning

www.merckmillipore.com/40years-steritest

“Conducting a test for sterility requires excellent work flows and a reliable test performance. The Merck Millipore SteritestTM system, with pump and filtration devices, supports the operators in a perfect manner to obtain reliable test results.”

Dr. Timo Krebsbach, Divison Manager Marketing & Sales, Labor L+S AG

 

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here